

Recurrent Bacterial Vaginosis Unresponsive To Metronidazole: Successful Treatment With Oral Clindamycin

Robyn Schuler Tepper, MD, Timothy J. Ives, PharmD, MPH,
and Mizanu Kebede, MS, MT (ASCP)

Bacterial vaginosis is known to be a polymicrobial condition that can include infections with *Gardnerella vaginalis*, *Mycoplasma hominis*, *Mobiluncus*, *Bacteroides*, and *Peptococcus*.¹ Currently, many physicians consider oral metronidazole to be the drug of choice for the treatment of bacterial vaginosis. Cure rates of up to 91 percent have been reported after 7 days of pharmacotherapy²; however, it is common and often frustrating for the clinician to see a lack of response after this standard treatment regimen. As recurrences are often attributed to poor compliance, cultures and sensitivity testing are not used routinely to address the possibility of resistant organisms. A case of recurrent bacterial vaginosis that contained a strain of *G. vaginalis* that was resistant to metronidazole is presented. Oral clindamycin was an effective alternative treatment.

Case Report

During a 5-year period, a 23-year-old patient was prescribed multiple courses of oral metronidazole 500 mg twice daily for 7 or 10 days for bacterial vaginosis. Initial treatment failures had been attributed to poor compliance, which was unsubstantiated. These infections were diagnosed by the characteristic vaginal discharge, presence of clue cells and absence of other pathogens on microscopic examination of the normal saline preparation on wet mounts, pH > 4.5, and an amine odor after the addition of 10 percent potassium hydroxide to the specimen. The patient continued to return to the clinic because of

the incomplete resolution of the vaginal discharge with the characteristic foul-smelling odor.

After the patient experienced repeated treatment failures with metronidazole in spite of total monogamy and the strict use of condoms during the treatment period, a vaginal swab was cultured on agar containing 5 percent defibrinated horse blood at 37°C with incubation in an anaerobic environment.³ Moderate normal genital tract flora were identified. Of note, however, *G. vaginalis* was also identified, with sensitivities as follows: penicillin G, 90 percent minimum inhibitory concentration (MIC₉₀) < 0.06 µg/mL; clindamycin, < 0.12 µg/mL; chloramphenicol, < 2 µg/mL; metronidazole, > 32 µg/mL; and tetracycline, > 16 µg/mL; the presence of a strain of *G. vaginalis* was resistant to both metronidazole and tetracycline but sensitive to clindamycin. No other anaerobic bacteria were identified. The patient was treated with oral clindamycin, 300 mg twice daily for 10 days. After 5 months, she remained asymptomatic and was culture negative for *G. vaginalis* at that point. She remained asymptomatic for 1 year, a longer recurrence-free period than any of the previous treatment courses with metronidazole.

Discussion

The standard MIC₉₀ of metronidazole for *G. vaginalis* is 32 µg/mL,³ but serum metronidazole concentrations of only 11.5 µg/mL have been found after administration of a 500-mg oral dose.⁴ Ralph, et al.⁵ demonstrated that 30 percent of *Gardnerella* strains were resistant under anaerobic conditions at a metronidazole MIC₉₀ of 16 µg/mL.⁵ Jones, et al.² found that 54.5 percent of strains had MIC₉₀ ≥ 32 µg/mL, but no correlation with treatment failures in relation to these strains has been made. Further studies examining the current sensitivity of *G. vaginalis* and other microbial organisms associated with bacterial vaginosis to metronidazole, as well as 1(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole, its active

Submitted, revised, 4 March 1994.

From the Student Health Service (RST), The Department of Family Medicine, School of Medicine, (TJI and MK), and the School of Pharmacy (TJI), University of North Carolina at Chapel Hill. Address reprint requests to Timothy J. Ives, PharmD, MPH, Department of Family Medicine, Box 7595, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7595.

hydroxy metabolite, are necessary to elucidate further the role of resistance in recurrent cases.

The use of clindamycin could be advantageous because of its high bacteriocidal activity against *G. vaginalis* and other associated anaerobic vaginal organisms,⁶⁻¹⁰ whereas metronidazole has high activity against *Bacteroides* strains, with only variable activity against *Mobiluncus*.^{2,10} Metronidazole is potentially dangerous for women who consume ethanol, because of the disulfiram-like reaction, or who are in their first trimester of pregnancy.¹¹ The risk of serious adverse reactions with clindamycin (e.g., pseudomembranous colitis) is considered to be low, and metronidazole has also been associated with this reaction.^{12,13} Careful monitoring for diarrhea while taking clindamycin could reduce the risk of developing a severe case of pseudomembranous colitis by discontinuing the suspected offending agent earlier.

Although the use of clindamycin in the treatment of bacterial vaginosis is not new, based upon our experience, clinicians should consider that organisms resistant to metronidazole might be the cause when patients have a recurrence of bacterial vaginosis after a confirmed treatment with a standard course of metronidazole. The latest report from the Centers for Disease Control and Prevention provides only a recommendation on the use of clindamycin as a vaginal cream at bedtime for 7 days during pregnancy,¹⁴ and oral clindamycin might be a reasonable alternative for patients who do not prefer to use vaginal products, cannot afford more costly antimicrobial products (e.g., in Chapel Hill, NC, the average cost to the patient for 2 percent clindamycin vaginal cream is \$30.05 versus \$15.60 for generic oral clindamycin capsules), or have failed a standard treatment course of oral metronidazole.

References

1. Eschenbach DA. Bacterial vaginosis: emphasis on upper genital tract complications. *Obstet Gynecol Clin North Am* 1989; 16:593-610.
2. Jones BM, Geary I, Alawattagama AB, Kinghorn GR, Duerden BI. In-vitro and in-vivo activity of metronidazole against *Gardnerella vaginalis*, *Bacteroides* spp and *Mobiluncus* spp in bacterial vaginosis. *J Antimicrob Chemother* 1985; 16:189-97.
3. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 2nd ed. Tentative standard. NCCLS publication M11-T2. Villanova, PA: NCCLS; 1989.
4. Ralph ED, Clarke JT, Libke RD, Luthy RP, Kirby WMM. Pharmacokinetics of metronidazole as determined by bioassay. *Antimicrob Agents Chemother* 1974; 6:691-6.
5. Ralph ED, Austin TW, Pattison FL, Schieven BC. Inhibition of *Haemophilus vaginalis* (*Corynebacterium vaginale*) by metronidazole, tetracycline, and ampicillin. *Sex Transm Dis* 1979; 6:199-202.
6. McCarthy LR, Mickelsen PA, Smith EG. Antibiotic susceptibility of *Haemophilus vaginalis* (*Corynebacterium vaginale*) to 21 antibiotics. *Antimicrob Agents Chemother* 1979; 16:186-9.
7. Greaves WL, Chungafung J, Morris B, Haile A, Townsend JL. Clindamycin versus metronidazole in the treatment of bacterial vaginosis. *Obstet Gynecol* 1988; 72:799-802.
8. Livengood CH 3rd, Thomason JL, Hill GB. Bacterial vaginosis: treatment with topical intravaginal clindamycin phosphate. *Obstet Gynecol* 1990; 76:118-23.
9. Hillier SL, Krohn MA, Watts DH, Wolner-Hanssen P, Eschenbach D. Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis. *Obstet Gynecol* 1990; 76:407-13.
10. Spiegel CA. Susceptibility of *Mobiluncus* species to 23 antimicrobial agents and 15 other compounds. *Antimicrob Agents Chemother* 1987; 31:249-52.
11. Robbie MO, Sweet RL. Metronidazole use in obstetrics and gynecology: a review. *Am J Obstet Gynecol* 1983; 145:865-81.
12. Fekety R, Kim KH, Brown D, Batts DH, Cudmore M, Silva J Jr. Epidemiology of antibiotic-associated colitis. Isolation of *Clostridium difficile* from the hospital environment. *Am J Med* 1981; 70:906-8.
13. Daly J, Chowdary KVJ. Pseudomembranous colitis secondary to metronidazole. *Dig Dis Sci* 1983; 28:573-4.
14. Centers for Disease Control. 1993 sexually transmitted diseases treatment guidelines. *MMWR* 1993; 42:(No. RR-14):68-70.